Guidelines
Clinical practice guidelines for the care of girls and women with Turner syndrome: Proceedings from the 2023 Aarhus International Turner Syndrome Meeting
Link : https://doi.org/10.1093/ejendo/lvae050
The Bigger Picture: More Than Short Stature
Turner Syndrome (TS) affects far more than height. It’s a lifelong, multi-organ condition impacting the heart, endocrine system, liver, and reproductive health. Many of its most serious risks—like aortic dilation—remain silent until advanced stages.
The 2024 guidelines mark a major shift toward a “Partnership in Care” model—where early action, personalized monitoring, and patient empowerment take center stage.
1. Growth Failure Starts Earlier Than We Thought
Growth delay in TS doesn’t begin in childhood—it starts before birth and accelerates in the first few years of life.
Waiting to monitor growth means missing a critical window. By age 3, much of the height deficit may already be irreversible.
What’s new:
- Growth hormone (GH) therapy can start as early as 2 years of age
- Early treatment helps maintain normal height trajectories
- Better alignment with peers during puberty
2. Heart Risk: Why Size Alone Misleads
Standard heart measurements don’t work well in TS. A “normal” aortic size in the general population can be dangerously large for someone with TS.
The shift: personalized metrics
- Aortic Size Index (ASI)
- Aortic Height Index (AHI)
- TS-specific Z-scores
These tools adjust for body size, enabling earlier detection of risk.
Red flags needing close monitoring:
- Bicuspid aortic valve
- Coarctation of aorta
- Hypertension
- Rapid aortic growth (>3 mm/year)
3. Hormone Therapy: Patch Over Pill
Not all estrogen replacement is equal.
The guidelines now strongly favor transdermal estradiol (patch) over oral therapy.
Why?
- Oral estrogen passes through the liver first
- This leads to potentially harmful metabolites
- The patch provides a more natural, steady hormone profile
Target levels in adults:
- Estradiol: 100–150 pg/mL
4. The NIPT Paradox
Non-invasive prenatal testing (NIPT) has changed screening—but for TS, it comes with a catch.
Key issue:
- Positive predictive value is only ~25%
- Many “positive” results are false alarms
What’s essential:
- NIPT is screening—not diagnosis
- Confirmation requires a 30-cell karyotype
5. Fertility: A Window That Needs Early Attention
Premature ovarian insufficiency is common in TS, making fertility preservation time-sensitive.
What’s new:
- Monitor Anti-Müllerian Hormone (AMH) from 8–9 years of age
- Identify early candidates for oocyte cryopreservation
But timing isn’t just biological—it’s emotional and ethical.
A New Era: From Management to Empowerment
The biggest shift in the 2024 guidelines isn’t just clinical—it’s philosophical.
Care is no longer reactive. It’s proactive, personalized, and collaborative.
A successful life with Turner Syndrome is no longer defined by limitations—but by:
- Early intervention
- Informed decision-making
- Lifelong multidisciplinary care
The future of TS care isn’t just about treating a condition—it’s about empowering individuals to live fully, confidently, and on their own terms.
Links to patient support group
Leave a Reply